XGEN PHARMS
GenericsXGEN PHARMS is a generic drug manufacturer focused on Oncology, Infectious Disease, Neurology.
XGEN PHARMS's Key Drugs
XGEN PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
XGEN PHARMS's Recent FDA Approvals
XGEN PHARMS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
XGEN PHARMS's Therapeutic Areas
XGEN PHARMS's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Infectious Disease, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
XGEN PHARMS's Top Competitors
XGEN PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Bristol-Myers Squibb. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
XGEN PHARMS Pipeline Snapshot
Active clinical trials for XGEN PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1992-04-29
- Latest
- 2026-03-16
- Applications
- 19